natgillin/translations-raw huggingface dataset:
A positive opinion was adopted by consensus on 21 June 2007. 
Pozitivno mnenje je bilo soglasno sprejeto 21. junija 2007.
OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR 
MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 29(4)1 ZA
The Czech Republic, Spain and Portugal referred the reasons for disagreement to the EMEA on 30 November 2006. 
Češka republika, Španija in Portugalska so svoje razloge za nesoglasje podale agenciji EMEA dne 30. novembra
The Marketing Authorisation Holder provided written explanations on 30 March 2007. 
Imetnik dovoljenja za promet z zdravilom je podal pisna pojasnila 30. marca 2007.
These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State. 
Države članice se glede skupnega priznavanja dovoljenja za promet z zdravilom, ki ga je podelila referenčna država članica, niso uspele dogovoriti.
The reasons for disagreement were, that some Member States have raised public health objections on the grounds that while bioequivalence was proven in the fasting state, the same was not the case under fed conditions. 
Razlogi za nesoglasje so bili v tem, da so imele nekatere države članice zadržke z vidika javnega zdravja, in sicer zaradi dejstva, da bioekvivalence, ki so jo sicer lahko dokazali pri osebah v teščem stanju, ni bilo mogoče dokazati pri osebah, ki niso bile tešče.
During their 18 - 21 June 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lansoprazole and associated names, that the objections raised by the Czech Republic, Spain and Portugal should not prevent the granting of a Marketing Authorisation and that the valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure. 
Med zasedanjem, ki je potekalo od 18. do 21. junija 2007, je bil odbor CHMP zaradi vseh predloženih podatkov in znanstvene razprave v odboru mnenja, da je razmerje med koristmi in tveganji za zdravilo Lansoprazole in z njim povezana imena ugodno, tako da zadržki Češke republike, Španije in Portugalske ne morejo preprečiti podelitve dovoljenja za promet z zdravilom, in da so trenutno veljavni Povzetek glavnih značilnosti zdravila, Označevanje in Navodilo za uporabo končne različice, ki so bile sprejete med postopkom skupine za usklajevanje.
TEVA UK Limited submitted applications for mutual recognition of Lansoprazole and associated names, 15 and 30 mg, gastro-resistant capsules, hard, on the basis of the marketing authorisation granted by the United Kingdom on 9 December 2005. 
Družba TEVA UK Limited je predložila vlogo za medsebojno priznavanje zdravila Lansoprazole in z njim povezanih imen, v obliki 15 in 30 mg gastrorezistentnih trdih kapsul, na podlagi dovoljenja za promet z zdravilom, ki ga je 9. decembra 2005 podelilo Združeno kraljestvo.
Lansoprazole 15 & 30 mg gastro-resistant capsules, hard are generic preparations containing lansoprazole as the active substance. 
Lansoprazole, 15 in 30 mg gastrorezistentne trde kapsule, je generično zdravilo, ki vsebuje zdravilno učinkovino lansoprazol.
Lansoprazole is a proton pump inhibitor that inhibits gastric acid secretion and is used for the treatment of duodenal and benign gastric ulcers, gastro-oesophageal reflux disease and associated conditions. 
Lansoprazol je zaviralec protonske črpalke, ki zavira izločanje želodčne kisline in se uporablja za zdravljenje razjed dvanajstnika in benignih želodčnih razjed, bolezni želodčno ezofagealnega refluksa in z njimi povezanih stanj.
You should usually receive your infusion once every 3 weeks. 
Običajno boste infuzijo prejeli enkrat vsake 3 tedne.
The use of gloves is recommended. 
Priporočamo uporabo rokavic.
Treatment may be delayed to allow sufficient time for recovery. 
Zdravljenje lahko odložimo, da omogočimo zadosten čas za okrevanje.
This combination should be used with caution. 
To kombinacijo moramo uporabljati previdno.
Pack of 1 vial. 
Pakiranje z 1 vialo.
The overall response rate was 14.1%. 
Povprečna stopnja odzivnosti je bila 14,1 %.
The infusion will last approximately 10 minutes. 
Infuzija bo trajala približno 10 minut.
• Stable disease (%) 
• Stabilna bolezen (%)
If necessary, creatinine clearance should be closely monitored. 
Po potrebi moramo skrbno spremljati očistek kreatinina.
The pH of the reconstituted solution is between 5.7 and 7.7. 
pH rekonstituirane raztopine je med 5,7 in 7,7.
*Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%. 
*Definicija pogostnosti: Zelo pogosto - > 10 %; Pogosto - > 5 % in < 10 %.
Female fertility was not investigated. 
Plodnosti pri ženskah niso raziskovali.
Sensitivity analyses of main efficacy endpoints were also assessed on the Protocol Qualified (PQ) population. 
Analize občutljivosti glavne končne točke učinkovitosti so ocenili tudi s protokolom kvalificirano (PK) populacijo.
However, it has been reported that pemetrexed may cause fatigue. 
Vendar pa so poročali, da lahko pemetreksed povzroči utrujenost.
The results of these analyses of efficacy are summarised in the table below. 
Izsledki teh analiz učinkovitosti so povzeti v spodnji preglednici:
Gently swirl each vial until the powder is completely dissolved. 
Vsako vialo narahlo vrtite, dokler prašek ni popolnoma raztopljen.
PFS data were partially confirmed by an independent review (400/1725 patients were randomly selected for review). 
PBN podatki so bili delno potrjeni z neodvisnim pregledom (400/1725 bolnikov je bilo naključno izbranih za pregled).
No dose reductions other than those recommended for all patients are necessary. 
Znižanja odmerkov, razen tistih, ki so priporočena za vse bolnike, niso potrebna.
Fisher's exact p-value* <0.001 
Fisherjeva točna p-vrednost* <0,001
In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili.
Thirst and increased water consumption 
Žeja in povečano pitje vode
There are many sorts of NSAIDs with different durations of activity. 
Obstaja veliko vrst NSAID-ov z različnimi trajanji delovanja.
Side effects with pemetrexed may include: 
Neželeni učinki s pemetreksedom lahko vključujejo:
Any diarrhoea requiring hospitalisation (irrespective of grade) or Grade 3 or 4 diarrhoea 
Kakršnakoli diareja, ki potrebuje hospitalizacijo (ne glede na stopnjo) ali diareja stopnje 3 ali 4
Rarely, skin reactions may be severe and could lead to death. 
Redko so kožne reakcije lahko hude in povzročijo lahko smrt.
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. 
Če ste noseči, mislite, da bi lahko bili noseči ali načrtujete nosečnost, to povejte svojemu zdravniku.
This medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment. 
To zdravilo vam dajemo, da bi zmanjšali pogostnost in resnost kožnih reakcij, ki jih lahko izkusite med zdravljenjem proti raku.
ATC code: L01BA04. 
Oznaka ATC: L01BA04
Based on the planned date of your infusion of pemetrexed and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. 
Na podlagi načrtovanega datuma vaše infuzije pemetrekseda in/ali glede na delovanje vaših ledvic vam mora vaš zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
There have been few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator. 
Poročali so o nekaj primerih ekstravazacije pemetrekseda, ki jih raziskovalec ni ocenil kot resne.
Anaphylactic shock (severe allergic reaction) 
Anafilaktični šok (huda alergijska reakcija)
Between-patient variability in clearance is moderate at 19.3%. 
Variabilnost med bolniki v očistku je zmerna, 19,3 %.
Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you. 
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Treatment should be resumed according to the guidelines in Table 2. 
Z zdravljenjem nadaljujemo skladno s smernicami v Preglednici 2.
Studies to assess the carcinogenic potential of pemetrexed have not been conducted. 
Študij za oceno kancerogenega potenciala pemetrekseda niso opravili.
Infection (sepsis) may be severe and could lead to death. 
Okužbe (sepse) so lahko hude in povzročijo lahko smrt.
In vitro studies indicate that pemetrexed is approximately 81% bound to plasma proteins. 
Študije in vitro kažejo, da se pemetreksed približno 81 % veže na plazemske beljakovine.
Animal studies have shown reproductive toxicity (see section 5.3). 
Študije na živalih so pokazale reproduktivno toksičnost (glejte poglavje 5.3).
Additional medicines 
Dodatna zdravila
Increased skin pigmentation 
Povečana pigmentiranost kože
The reporting rates shown are according to CTCAE version 3.0. 
Prikazana pogostnost navedb je skladna s CTCAE, verzija 3.0.
Patients received maintenance treatment until disease progression. 
Bolniki so prejeli vzdrževalno zdravljenje do napredovanja bolezni.
Log rank p-value* 
Log rank p-vrednost*
Pemetrexed can have genetically damaging effects. 
Pemetreksed ima lahko genetsko škodljive učinke.
Be careful when driving a car or using machines. 
Pri vožnji ali upravljanju strojev bodite previdni.
Your doctor will use this body surface area to work out the right dose for you. 
Zdravnik bo uporabil to izračunano površino vašega telesa za določitev pravega odmerka za vas.
The infusion of cisplatin will last approximately 2 hours. 
Infuzija cisplatina traja približno 2 uri.
Survival time (months) 
Čas preživetja (meseci)
The effect of third-space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined. 
Učinek tekočine tretjega prostora, denimo plevralnega izliva ali ascitesa, na pemetreksed ni popolnoma opredeljen.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
V vsaki skupini pogostnosti so neželeni učinki navedeni po padajoči resnosti.
The percentage of patients that received post-study treatment was 64.3% for pemetrexed and 71.7% for placebo. 
Odstotek bolnikov, ki so prejeli zdravljenje po študiji, je bil 64,3 % za pemetreksed in 71,7 % za placebo.
Statistically significant differences in pulmonary function tests were also observed. 
Opažali so tudi statistično značilne razlike v testih pljučnega delovanja.
Do not use Pemetrexed Pfizer - if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Pemetreksed Pfizer - če ste alergični na pemetreksed ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Driving and using machines Pemetrexed Pfizer may make you feel tired. 
Vpliv na sposobnost upravljanja vozil in strojev Pemetreksed Pfizer lahko povzroči, da se boste počutili utrujene.
In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. 
V kliničnih študijah ni kazalo, da bi bili bolniki, stari 65 let ali več, bolj izpostavljeni tveganju za neželene učinke v primerjavi z bolniki, mlajšimi od 65 let.
Time to treatment failure (TTTF - months) 
Čas do neuspeha zdravljenja (Time to treatment failure, TTTF - meseci)
Contains mannitol 
Vsebuje manitol.
Your doctor will discuss with you the potential risk of taking pemetrexed during pregnancy. 
Z zdravnikom se pogovorite o možnem tveganju pri prejemanju pemetrekseda v času nosečnosti.
ITT population and histology subgroups 
NZ populacija in histološke podskupine
Creatinine clearance should be ≥ 45 ml/min. 
Očistek kreatinina mora biti ≥ 45 ml/min.
The doctor or hospital pharmacist will work out the dose you need based on your height and weight. 
Zdravnik ali bolnišnični farmacevt bo določil potrebni odmerek na podlagi vaše telesne višine in mase.
Use in combination with cisplatin 
Uporaba v kombinaciji s cisplatinom
Further dilution is required, as below. 
Raztopino je treba še dodatno razredčiti, kot je opisano spodaj.
Frequency estimate: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from available data). 
Pogostnosti so določene kot: zelo pogosto (≥1/10), pogosto (≥ 1/100 in < 1/10), občasno (≥ 1/1.000 in < 1/100), redko (≥ 1/10.000 in < 1/1.000), zelo redko (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov-spontanih poročil).
Loss of appetite 
Izguba apetita
Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): Risk of systemic, possibly fatal, disease. 
Živa oslabljena cepiva (razen proti rumeni mrzlici, za katero je sočasna uporaba kontraindicirana): tveganje za sistemsko, potencialno smrtno bolezen.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing pemetrexed in all subsets of the paediatric population for the granted indications (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z referenčnim zdravilom, ki vsebuje pemetreksed, za vse skupine pediatrične populacije za odobrene indikacije (za informacije o pediatrični uporabi glejte poglavje 4.2).
100% of previous dose 
100% predhodnega odmerka
- if you have recently received or are about to receive a vaccine against yellow fever. 
- če ste bili nedavno cepljeni ali boste kmalu cepljeni proti rumeni mrzlici.
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs. 
Če niste prepričani, vprašajte svojega zdravnika ali farmacevta, ali so katera od vaših zdravil NSAID-i.
This leaflet was last revised in month YYYY. 
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
Further dilution is required. 
Raztopino je treba še dodatno razredčiti.
The primary efficacy analysis was based on the ITT population. 
Prvotna analiza učinkovitosti je bila osnovana na NZ populaciji.
Particular attention should be paid to these patients, and caution exercised with use of other radiosensitising agents. 
Pri teh bolnikih je potrebna posebna pozornost in previdnost pri uporabi drugih radiosenzitirajočih učinkovin.
Efficacy and safety were measured from the time of randomisation after completion of first-line (induction) therapy. 
Učinkovitost in varnost sta bili merjeni od časa randomizacije po zaključku zdravljenja prve izbire (indukcije).
The total bilirubin should be ≤ 1.5-times upper limit of normal. 
Celotni bilirubin mora biti ≤ 1,5-kratnika zgornje meje normalnih vrednosti.
All grades toxicity(%) 
Toksičnost vseh stopenj (%)
The 1 year and 2 year survival rates for patients on pemetrexed were 58% and 32% respectively, compared to 45% and 21% for patients on placebo. 
Stopnji preživetja pri 1 in pri 2 letih pri bolnikih, ki so prejemali pemetreksed, sta bili 58 % in 32 %, v primerjavi s 45 % in 21 % pri bolnikih, ki so prejemali placebo.
The pemetrexed maintenance safety profiles from the two studies JMEN and PARAMOUNT were similar. 
Profila varnosti vzdrževalnega zdravljenja s pemetreksedom iz obeh študij, JMEN in PARAMOUNT, sta bila podobna.
It is not known whether pemetrexed is excreted in human milk, and adverse reactions on the breast-feeding child cannot be excluded. 
Dojenje Ni znano, ali se pemetreksed izloča v materino mleko, in neželenih reakcij za dojenčka ne moremo izključiti.
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen). 
Prosimo, povejte svojemu zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID-i), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).
Therefore, patients should be cautioned against driving or operating machines if this event occurs. 
Zato je treba bolnike opozoriti, da naj ne vozijo in upravljajo strojev, če se pojavi utrujenost.
Pemetrexed is primarily eliminated in the urine, with 70% to 90% of the administered dose being recovered unchanged in urine within the first 24 hours following administration. 
Pemetreksed se primarno izloča z urinom, 70 % do 90 % danega odmerka najdemo nespremenjenega v urinu v prvih 24 urah po dajanju.
Many of the patients in whom these occurred had underlying risk factors for the development of renal events, including dehydration or pre-existing hypertension or diabetes. 
Mnogi bolniki, pri katerih so se le-ti pojavili, so imeli v osnovi dejavnike tveganja za razvoj ledvičnih primerov, vključno z dehidracijo ali že prej obstoječo hipertenzijo ali diabetesom.
If you have heart disease or a history of heart disease, please tell your doctor. 
Če imate bolezen srca ali če ste v preteklosti imeli bolezen srca, prosimo, da to poveste zdravniku.
Pre-medication regimen 
Režim premedikacije
No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. 
Ugotovili niso nobenih razmerij med AST (SGOT), ALT (SGPT), ali celokupnim bilirubinom in farmakokinetiko pemetrekseda.
Vitamin B12 and folic acid are given to you to reduce the possible toxic effects of the anticancer treatment. 
Vitamin B12 in folno kislino boste prejeli za zmanjšanje možnih toksičnih učinkov zdravljenja proti raku.
Taste change 
Sprememba okusa
Children and adolescents There is no relevant use of pemetrexed in the paediatric population. 
Otroci in mladostniki Pemetreksed ni primeren za uporabo pri pediatrični populaciji.
Polyglutamation is a time- and concentration-dependent process that occurs in tumour cells and, to a lesser extent, in normal tissues. 
Poliglutamacija je proces, odvisen od časa in koncentracije, ki se dogaja v tumorskih celicah, in v manjšem obsegu v normalnih tkivih.
Calculate the dose and the number of Pemetrexed Pfizer vials needed. 
Izračunajte odmerek in število potrebnih vial zdravila Pemetreksed Pfizer.
Most of these events resolved after pemetrexed withdrawal. 
Večina od teh dogodkov je po prekinitvi zdravljenja s pemetreksedom izzvenela.
If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression and gastrointestinal toxicity. 
Če je sočasno dajanje NSAID-ov potrebno, je pri bolnikih potrebno skrbno spremljati toksičnost, predvsem mieolosupresijo in gastrointestinalno toksičnost.
All patients included in this study had an ECOG performance status 0 or 1. 
Vsi bolniki, vključeni v to študijo, so imeli ECOG status učinka 0 ali 1.
Upon recovery, patients should be re-treated using the guidelines in Tables 1, 2, and 3, which are applicable for pemetrexed used as a single agent or in combination with cisplatin. 
Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za pemetreksed, če jo uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. 
Povejte svojemu zdravniku ali bolnišničnemu farmacevtu, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
You may want to seek counselling on sperm storage before starting your therapy. 
Morda se boste želeli pred začetkom zdravljenja posvetovati o shranjevanju sperme.
In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter). 
In vitro študije so pokazale, da se pemetreksed aktivno izloča z OAT3 (prenašalcem organskih anionov).
Pemetrexed total systemic exposure (AUC) and maximum plasma concentration increase proportionally with dose. 
Celotna sistemska izpostavljenost pemetreksedu (AUC) ter največja plazemska koncentracija naraščata sorazmerno z odmerkom.
The polyglutamate forms are retained in cells and are even more potent inhibitors of TS and GARFT. 
Poliglutamatne oblike se zadržujejo v celicah in so še močnejši zaviralci TS in GARFT.
Safety was assessed for patients who were randomised to receive pemetrexed (N=800). 
Varnost je bila ocenjena pri bolnikih, ki so bili naključno izbrani za prejemanje pemetrekseda (N=800).
The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anti-cancer chemotherapy require increased frequency of INR (International Normalised Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants. 
Velika različnost med posamezniki v koagulacijskem statusu v času bolezni ter možnost medsebojnega delovanja med peroralnimi antikoagulacijskimi učinkovinami ter kemoterapijo proti raku zahtevata povečano pogostnost spremljanja INR (International Normalised Ratio), če se odločimo za zdravljenje bolnika s peroralnimi antikoagulacijskimi učinkovinami.
The other ingredient is mannitol. 
Druga sestavina zdravila je manitol.
** Which is derived from the term “renal/genitourinary other”. 
** izhaja iz izraza “ledvični/sečila drugo”.
Pemetrexed should not be used during pregnancy unless clearly necessary, after a careful consideration of the needs of the mother and the risk for the foetus (see section 4.4). 
Pemetrekseda med nosečnostjo ne smemo uporabljati, če to ni neobhodno potrebno, uporabimo pa ga le po skrbni preučitvi potreb matere in tveganja za plod (glejte poglavje 4.4).
Use an inactivated vaccine where it exists (poliomyelitis) (see section 4.4). 
Uporabite inaktivirano cepivo, če to obstaja (poliomielitis) (glejte poglavje 4.4).
Kaplan-Meier plots of overall survival by histology 
Kaplan-Meier-jeva grafa skupnega preživetja glede na histologijo
If a pemetrexed solution contacts the skin, wash the skin immediately and thoroughly with soap and water. 
Če pride raztopina pemetrekseda v stik s kožo, kožo nemudoma in temeljito sperite z milom in vodo.
Pemetrexed is not a vesicant. 
Pemetreksed ni mehurjevec.
No statistically significant differences in any other individual Grade 3/4/5 adverse reactions were seen with longer exposure. 
Pri drugih posameznih neželenih učinkih stopnje 3/4/5 pa ni bilo zaznati statistično značilnih razlik pri dolgotrajnejši izpostavljenosti.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase. 
Okrajšave: ALT = alaninska aminotransferaza; AST = aspartatna aminotransferaza; CTCAE = običajni terminološki kriteriji za neželene učinke; NCI = nacionalni inštitut za rakava obolenja; SGOT = serumska glutamat oksalocetna aminotransferaza; SGPT = serumska glutamat piruvična aminotransferaza.
Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. 
Ko je enkrat v celici, se pemetreksed hitro in učinkovito pretvori z encimom folilpoliglutamatno sintetazo v poliglutamatne oblike.
There are no data from the use of pemetrexed in pregnant women; but pemetrexed, like other anti-metabolites, is suspected to cause serious birth defects when administered during pregnancy. 
Podatkov o uporabi pemetrekseda pri nosečnicah ni, a za pemetreksed, kot za druge antimetabolite, sumimo, da povzroča resne prirojene okvare, če ga dajemo med nosečnostjo.
Subsequent vitamin B12 injections may be given on the same day as pemetrexed. 
Kasnejše injekcije vitamina B12 lahko dajemo isti dan kot pemetreksed.
The use of pemetrexed should be avoided during pregnancy. 
Uporabi pemetrekseda med nosečnostjo se izogibamo.
Response (n: qualified for response) 
Odziv (N: ustrezen odziv)